Diabetics with thin-cap fibroatheroma on OCT at high CV risk despite negative FFR: Study
Patients with diabetes who have a thin-cap fibroatheroma (TCFA) coronary lesion have a significant increase in adverse cardiac events despite negative findings on FFR, suggests a study published in the European Heart Journal.
A group of European researchers conducted a study to understand the impact of optical coherence tomography (OCT)-detected thin-cap fibroatheroma (TCFA) on clinical outcomes of diabetes mellitus (DM) patients with fractional flow reserve (FFR)-negative lesions.
The study named OMBINE OCT-FFR was a prospective, double-blind, international, natural history study. After FFR assessment, and revascularization of FFR-positive lesions, patients with ≥1 FFR-negative lesion (target lesions) were classified into two groups based on the presence or absence of ≥1 TCFA lesion.
The primary endpoint compared FFR-negative TCFA-positive patients with FFR-negative TCFA-negative patients for a composite of cardiac mortality, target vessel myocardial infarction, clinically driven target lesion revascularization or unstable angina requiring hospitalization at 18 months.
The results of the study are as follows:
- Among 550 patients enrolled, 390 (81%) patients had ≥1 FFR-negative lesion. Among FFR-negative patients, 98 (25%) were TCFA positive and 292 (75%) were TCFA negative.
- The incidence of the primary endpoint was 13.3% and 3.1% in TCFA-positive vs. TCFA-negative groups, respectively.
- The Cox regression multivariable analysis identified TCFA as the strongest predictor of major adverse clinical events (MACE)
Thus, the researchers concluded that among Diabetes mellitus patients with ≥1 FFR-negative lesions, TCFA-positive patients represented 25% of this population and were associated with a five-fold higher rate of MACE despite the absence of ischaemia. This discrepancy between the impact of vulnerable plaque and ischaemia on future adverse events may represent a paradigm shift for coronary artery disease risk stratification in Diabetes mellitus patients.
Reference:
Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT–FFR trial by Kedhi, E et. al published in the European Heart Journal.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.